Amarin Corp Plc (AMRN)

[couldbebetter]

Bill B, From my limited understanding of the process, Germany is normally
the first country that will be used to negotiate the pricing for Vascepa
and then being approved. This would explain the positions for Germany.
One might ask what about the other countries? Why no new hires for them?
My guess is that it could be a ruse, hiring the minimum number of
people to get the drug approved while (in reality) you are working
out the best deal possible for either a JV or BP BO. AMRN will not be
hiring another 800 sales reps to sell Vascepa in Europe. Companies
based in Europe such as Roche & Novartis have been selling drugs there
for decades...they know what to do...AMRN simply would fail if it
were truly a GIA for real. As I have said many times before, the
sooner BP acquires AMRN for Europe, the more money they will ultimately
make. The right BP could make Vascepa into a mega-blockbuster drug...
if they want to. Let us hope some BP are well aware of Vascepa and
its potential for CVD, COVID-19, and perhaps even other indications
they could go after. If there were such interest, there may not be
the need to hire an investment bank for now...if the interest is
not already there, then it would be insane not to have an IB.